geko system could save up to £200 per patient
geko can help improve treatment pathways for people at risk of VTE
A device that could help to reduce the risk of a blood clot forming in a deep vein of the legs is being supported by new NICE guidance published this week.
The medical technology guidance supports the geko device being used in people who have a high risk of venous thromboembolism (VTE), where standard methods of preventing blood clots aren’t suitable or can’t be used.
Some patients are at high risk of VTE, but have conditions such as peripheral arterial disease or dermatitis, which means that they would not be able to use the anti-embolism stockings commonly given to prevent blood clots. Where drugs to prevent clots also can’t be used, the geko device provides an option for patients who would otherwise be unable to receive treatment to reduce the risk of blood clots in the leg.
Using the device in this situation where no standard alternatives are available is likely to reduce the high risk of VTE and so is estimated to save nearly £200 per patient compared with no preventative treatment.
Professor Carole Longson, director of the NICE Centre for Health Technology Evaluation, said: “This guidance is good news for patients at high risk of deep vein blood clots in the leg who can’t use standard prevention methods.
“The Medical Technologies Advisory Committee decided that although the clinical evidence is limited, it was plausible that the geko device may reduce the high risk of VTE in patients who can’t use other forms of blood clot prevention. The additional low risk of the device causing any harm resulted in the guidance supporting routine NHS use of the device for patients at high VTE risk who have no preventative options. Using the device in this way is estimated to save £197 per patient. This guidance encourages the NHS to consider using the geko device for patients at high VTE risk where other methods of risk reduction aren’t suitable.”
If a blood clot blocks a vein deep in the body, this is commonly known as a deep vein thrombosis (DVT). If a blood clot breaks away it may travel to the lungs and cause a blockage there – a potentially-fatal pulmonary embolism. VTE covers both deep vein thrombosis (DVT) and its possible consequence, pulmonary embolism.
The geko device, which is manufactured by Firstkind, is similar in size and appearance to a small wristwatch, and is fixed to the back of the knee joint via its adhesive surface. The disposable, battery-powered device creates electrical impulses to stimulate a nerve in the leg, causing muscles to contract and so increasing the blood flow in the veins. This imitates the changes in blood flow normally achieved by walking, but without the person having to move.
The claimed benefits of the geko device in the case for adoption presented by the device manufacturer include reducing the risk of VTE by preventing and reducing slow blood flow in the veins, the device being discreet and comfortable to wear allowing the person to remain mobile, and providing an alternative means of VTE risk reduction for patients who can’t use standard methods.
Click here to read the full guidance.